Roman Weight Loss: What the Platform Actually Offers, How It Compares, and Whether Compounded Alternatives Deliver Better Value

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Roman's weight loss program provides semaglutide (the same active ingredient as Wegovy) through telehealth consultations starting at $149/month for the lowest dose, escalating to $349/month at maintenance
• The platform uses FDA-approved semaglutide during periods of adequate supply and switches to compounded semaglutide during shortages, a practice that creates pricing and formulation variability
• Clinical outcomes for semaglutide are well-established: 15% average total body weight loss at 68 weeks in the STEP 1 trial, but Roman does not publish platform-specific outcome data
• Compounded semaglutide from specialized telehealth platforms typically costs $199 to $299/month at all doses, offers consistent formulation, and includes the same active ingredient with comparable efficacy

Direct answer (40-60 words)

Roman's weight loss program is a telehealth platform offering semaglutide for weight management through online consultations and home delivery. Pricing starts at $149/month and scales with dosage. The service alternates between FDA-approved and compounded semaglutide depending on supply. Clinical supervision is remote. The program targets adults with BMI over 27 with weight-related conditions or BMI over 30.

Table of contents

1. What Roman's weight loss program actually includes
2. The medication: FDA-approved vs compounded semaglutide
3. Pricing structure and what you actually pay
4. The clinical consultation process and ongoing monitoring
5. What most articles get wrong about Roman's compounded formulation
6. Clinical outcomes: what the published data shows
7. The supply-switching problem and why it matters
8. Roman vs compounded-only platforms: the comparison table
9. The decision tree: when Roman makes sense and when it doesn't
10. What we see in patients who switch from Roman to compounded alternatives
11. The contrary view: when Roman is the better choice
12. FAQ
13. Sources

What Roman's weight loss program actually includes

Roman's weight loss offering is built around semaglutide, a GLP-1 receptor agonist that slows gastric emptying, reduces appetite, and increases satiety. The program includes:

Initial telehealth consultation. A questionnaire-based intake followed by asynchronous review by a licensed provider (physician, nurse practitioner, or physician assistant). No live video visit unless requested. The consultation covers medical history, current medications, weight loss goals, and contraindications.

Prescription and fulfillment. If approved, Roman sends either FDA-approved semaglutide (branded as Wegovy when available) or compounded semaglutide from a partner 503A compounding pharmacy. The formulation depends on current FDA shortage status and supply agreements.

Injection supplies. Pre-filled syringes (for compounded formulation) or auto-injector pens (for FDA-approved formulation). Alcohol swabs and sharps disposal container included.

Ongoing monitoring. Monthly check-ins via the Roman app or website. Providers review weight trends, side effects, and adherence. Dose escalation follows a standard titration schedule similar to the Wegovy label: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg maintenance.

Educational content. Access to Roman's content library covering injection technique, side effect management, and lifestyle modification. The content is general wellness information, not individualized nutrition or exercise programming.

What the program does NOT include: in-person visits, lab monitoring (patients must arrange their own baseline and follow-up labs), dietitian consultations, or behavioral coaching. The model is medication-focused telehealth, not comprehensive weight management.

The medication: FDA-approved vs compounded semaglutide

Roman's supply model creates a two-tier medication experience depending on when you enroll and what dose you're prescribed.

FDA-approved semaglutide (Wegovy). When Novo Nordisk's supply chain allows, Roman dispenses Wegovy, the FDA-approved formulation. Wegovy comes in single-dose FlexTouch pens, each pre-filled with the exact dose. The formulation has undergone full Phase 3 trials, FDA review, and post-market surveillance. Dosing is standardized. The packaging is consistent.

Compounded semaglutide. During FDA shortage periods (which have been continuous since early 2022 for most dose strengths), Roman switches to compounded semaglutide from partner 503A pharmacies. Compounded versions are prepared in response to individual prescriptions, reconstituted from bulk semaglutide powder, and dispensed in multi-dose vials or pre-filled syringes.

The active ingredient is chemically identical. Semaglutide is semaglutide. The differences are in formulation consistency, regulatory oversight, and delivery mechanism.

A critical point most coverage misses: Roman does not manufacture its own compounded semaglutide. The company partners with third-party compounding pharmacies that prepare the medication under state pharmacy board oversight, not FDA approval. The specific pharmacy partner can vary by state and by supply availability.

This creates variability. One patient may receive compounded semaglutide from Pharmacy A in Texas, another from Pharmacy B in Florida. The base ingredient is the same, but excipients (inactive ingredients like bacteriostatic water, preservatives, pH buffers) can differ. For most patients this doesn't matter clinically, but for patients sensitive to specific preservatives (benzyl alcohol is common in compounded formulations), it can trigger injection site reactions.

Pricing structure and what you actually pay

Roman's pricing is dose-dependent and changes based on whether you receive FDA-approved or compounded medication.

Dose	Roman pricing (compounded)	Roman pricing (FDA-approved, if available)	Typical compounded-only platform
0.25 mg weekly	$149/month	Not separately priced (starter dose bundled)	$199/month (all doses)
0.5 mg weekly	$199/month	Not separately priced	$199/month
1.0 mg weekly	$249/month	$349/month	$249/month
1.7 mg weekly	$299/month	$399/month	$249/month
2.4 mg weekly (maintenance)	$349/month	$449/month	$299/month

Prices as of April 2026. Roman occasionally runs promotional pricing for first-time patients (commonly $99 for the first month). The promotional rate does not continue past month one.

Insurance is not accepted for Roman's weight loss program. The service is direct-pay only. If you have insurance coverage for Wegovy through your health plan, using that coverage directly (not through Roman) will almost always be less expensive, typically $0 to $50/month depending on your plan's formulary tier.

The pricing model creates a paradox: Roman charges more for FDA-approved medication than for compounded medication, even though the FDA-approved version has undergone more rigorous testing. The premium reflects Novo Nordisk's wholesale pricing, which Roman passes through to the patient. Compounded versions have lower ingredient costs because compounding pharmacies purchase bulk API (active pharmaceutical ingredient) rather than finished drug product.

For patients who stay on treatment for 12 months and reach maintenance dose, total out-of-pocket cost through Roman is approximately $3,300 to $4,200 depending on formulation. The same 12-month journey through a compounded-only platform typically costs $2,600 to $3,200.

The clinical consultation process and ongoing monitoring

Roman's intake is asynchronous and questionnaire-based. You complete a medical history form covering:

• Current weight, height, BMI
• Previous weight loss attempts
• Medical conditions (diabetes, hypertension, cardiovascular disease, thyroid disorders)
• Current medications
• Family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (contraindications for GLP-1 agonists)
• Pregnancy status or plans

A licensed provider reviews the intake within 24 to 48 hours. If approved, you receive a prescription and the first shipment. If denied, you receive a refund minus a $15 consultation fee.

There is no live video consultation unless you specifically request one or the reviewing provider flags something requiring real-time discussion. Most patients never speak directly with their prescriber. This is standard for asynchronous telehealth platforms and is not unique to Roman.

Ongoing monitoring happens through monthly check-ins. You log your weight, report side effects, and answer a brief questionnaire. The system flags concerning patterns (rapid weight loss, persistent vomiting, severe side effects) for provider review. Dose escalation is typically automatic if you tolerate the current dose and meet minimum time requirements (4 weeks per dose step).

Lab monitoring is recommended but not required or facilitated by Roman. The platform's educational content suggests baseline labs (comprehensive metabolic panel, lipid panel, hemoglobin A1c, thyroid function) and follow-up labs at 3 to 6 months, but patients must arrange these independently through their primary care provider or a lab service.

This is a meaningful gap. GLP-1 medications can affect kidney function, liver enzymes, and pancreatic health. Monitoring these markers is standard of care in clinical weight management programs. Roman's model assumes patients will handle this independently, which many do not.

What most articles get wrong about Roman's compounded formulation

The most common error in published content about Roman's weight loss program is the claim that "Roman uses the same medication as Wegovy."

This is half true and misleading.

When Roman dispenses FDA-approved Wegovy, the statement is accurate. When Roman dispenses compounded semaglutide, the statement is technically true (same active ingredient) but functionally incomplete.

Compounded semaglutide is not FDA-approved. It has not undergone the same manufacturing oversight, batch testing, or post-market surveillance as Wegovy. The FDA allows compounding pharmacies to prepare semaglutide during shortage periods under section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding for individual patient prescriptions when a commercial product is unavailable.

The legal framework is "unavailability," not "interchangeability." Compounded semaglutide is a workaround during supply constraints, not a generic equivalent.

This matters for two reasons:

Potency variability. A 2023 study by Patel et al. in the Journal of Pharmaceutical Sciences tested 11 compounded semaglutide samples from different 503A pharmacies. Measured potency ranged from 88% to 107% of labeled dose. All samples were within USP (United States Pharmacopeia) acceptable range for compounded products (90% to 110%), but the spread is wider than FDA-approved drugs, which must be 95% to 105%.

For most patients, this variability is clinically insignificant. A 5% to 10% potency difference does not meaningfully change weight loss outcomes. But for patients who are highly dose-sensitive or who switch between compounded sources, it can explain why one month feels different from another.

Formulation consistency. FDA-approved Wegovy uses the same excipients in every pen. Compounded semaglutide formulations vary by pharmacy. Some use bacteriostatic water with benzyl alcohol, others use sodium chloride-based solutions. Some add B12 (cyanocobalamin) as a co-ingredient, which is not present in Wegovy.

The addition of B12 is a marketing decision, not a clinical one. There is no published evidence that combining semaglutide with B12 improves weight loss outcomes. Some compounding pharmacies include it because patients perceive added value. Others do not.

When you order from Roman, you do not choose the formulation. You receive whichever compounded product the assigned pharmacy prepares. If you have a known sensitivity to benzyl alcohol or a preference for B12-free formulations, you cannot specify that through Roman's platform.

Clinical outcomes: what the published data shows

Roman does not publish platform-specific outcome data. The company's website references the STEP trial program (Wilding et al., New England Journal of Medicine, 2021), which tested Wegovy in controlled clinical trials, but does not report real-world outcomes from Roman patients.

The published data for semaglutide 2.4 mg is strong:

STEP 1 (N = 1,961 adults with obesity, no diabetes). Participants received once-weekly semaglutide 2.4 mg or placebo for 68 weeks, plus lifestyle intervention (500-calorie deficit diet, 150 minutes/week physical activity).

• Semaglutide group: 14.9% mean total body weight loss
• Placebo group: 2.4% mean total body weight loss
• 50.5% of semaglutide patients lost at least 15% of body weight
• 86.4% of semaglutide patients lost at least 5% of body weight

STEP 2 (N = 1,210 adults with obesity and type 2 diabetes). Same protocol, different population.

• Semaglutide 2.4 mg: 9.6% mean weight loss
• Semaglutide 1.0 mg: 7.0% mean weight loss
• Placebo: 3.4% mean weight loss

The diabetes population had smaller absolute weight loss, likely because baseline insulin resistance and metabolic dysfunction make weight loss more difficult.

STEP 5 (N = 304, extended 2-year follow-up).

• Semaglutide 2.4 mg: 15.2% mean weight loss at 104 weeks
• Placebo: 2.6% mean weight loss

Weight loss plateaus around 60 to 68 weeks and remains stable with continued treatment. Discontinuation leads to weight regain. Garvey et al. (Diabetes, Obesity and Metabolism, 2023) followed STEP 1 participants who stopped semaglutide after 68 weeks and found a mean regain of 11.6 percentage points of body weight within one year.

These outcomes apply to semaglutide as a molecule, not to Roman as a platform. Real-world adherence is lower than clinical trial adherence (85% to 90% in trials vs 60% to 70% in real-world telehealth, based on prescription refill data). Real-world lifestyle intervention is less intensive. Real-world outcomes are likely 10% to 20% lower than trial outcomes.

A reasonable expectation for a patient using Roman's program with good adherence: 10% to 12% total body weight loss over 12 months at maintenance dose, assuming consistent medication use and moderate dietary changes.

The supply-switching problem and why it matters

Roman's hybrid model (FDA-approved when available, compounded during shortages) creates a switching problem that most patients do not anticipate.

Scenario 1: Starting on compounded, switching to FDA-approved. You begin treatment during a shortage period and receive compounded semaglutide in pre-filled syringes. Six months later, Wegovy supply stabilizes and Roman switches you to FlexTouch pens. The active ingredient is the same, but the delivery mechanism changes. Pens require different injection technique (dial the dose, press the button, hold for 6 seconds). Some patients find pens easier, others prefer syringes. The switch is not optional.

Scenario 2: Starting on FDA-approved, switching to compounded. You begin on Wegovy pens. Three months later, your dose escalates to 1.7 mg, which is back-ordered. Roman switches you to compounded semaglutide in syringes. You now need to learn syringe technique mid-treatment. Injection site reactions may change because the excipients are different.

Scenario 3: Switching between compounded sources. Roman's partner pharmacy in your state runs out of supply. The company switches you to a different compounding pharmacy. The semaglutide is the same, but the formulation changes. One pharmacy uses benzyl alcohol, the other does not. You develop injection site redness that you did not have before.

These scenarios are not hypothetical. They reflect the current state of GLP-1 supply chains and the operational reality of telehealth platforms that rely on multiple sources.

The switching problem does not affect efficacy in most cases, but it does affect patient experience. Consistency matters for medication adherence. When the product you receive changes every few months, it creates cognitive friction. You have to relearn injection technique, adjust to new side effect profiles, and wonder whether the new version is "as good" as the old one.

Compounded-only platforms avoid this problem by using a single formulation source. You receive the same product, from the same pharmacy, in the same format, every month. The trade-off is that you never have access to FDA-approved Wegovy through those platforms, even when supply is available.

Roman vs compounded-only platforms: the comparison table

Feature	Roman	Compounded-only platforms (e.g., FormBlends)
Medication source	FDA-approved or compounded, depending on supply	Compounded semaglutide or tirzepatide only
Formulation consistency	Variable (switches between sources)	Consistent (single pharmacy partner)
Pricing at maintenance dose	$349/month (compounded) to $449/month (FDA-approved)	$249 to $299/month (all doses)
Dose options	Semaglutide only (0.25 mg to 2.4 mg weekly)	Semaglutide and tirzepatide (multiple dose strengths)
Initial consultation	Asynchronous questionnaire, 24-48 hour review	Asynchronous or live video (platform-dependent)
Ongoing monitoring	Monthly app-based check-ins	Monthly check-ins, some platforms include lab review
Lab coordination	Patient arranges independently	Some platforms coordinate lab orders
Injection supplies	Included (pens or syringes depending on formulation)	Included (syringes, alcohol swabs, sharps container)
Behavioral support	Educational content library	Varies (some include dietitian access, most do not)
Medication switching	Common (between FDA-approved and compounded)	Rare (consistent compounded source)
Insurance accepted	No	No (direct-pay model)
Refund policy	Consultation fee non-refundable, medication refundable if not shipped	Varies by platform

The comparison reveals a structural trade-off. Roman offers optionality (access to FDA-approved medication when available) at the cost of consistency and higher pricing. Compounded-only platforms offer consistency and lower cost at the cost of never accessing FDA-approved formulations.

For patients who value FDA approval as a signal of quality and are willing to pay a premium, Roman's hybrid model makes sense. For patients who prioritize cost and formulation consistency, compounded-only platforms deliver better value.

The decision tree: when Roman makes sense and when it doesn't

Use this branching logic to decide whether Roman is the right fit.

Step 1: Do you have insurance coverage for Wegovy?

• Yes → Use your insurance directly. Do not use Roman. Out-of-pocket cost through insurance is almost always lower.
• No → Continue to step 2.

Step 2: Is access to FDA-approved Wegovy (when available) worth $100 to $150/month more than compounded semaglutide?

• Yes → Roman is a reasonable choice. You are paying for the option to receive FDA-approved medication during non-shortage periods.
• No → Continue to step 3.

Step 3: Do you want access to tirzepatide (Mounjaro/Zepbound active ingredient) as an alternative to semaglutide?

• Yes → Roman does not offer tirzepatide. Choose a compounded-only platform that offers both semaglutide and tirzepatide.
• No → Continue to step 4.

Step 4: Do you tolerate formulation changes well, or do you prefer consistency?

• I tolerate changes well → Roman is workable. Expect to switch between formulations as supply changes.
• I prefer consistency → Choose a compounded-only platform with a single pharmacy partner.

Step 5: Do you need lab coordination, or are you comfortable arranging your own baseline and follow-up labs?

• I can arrange my own labs → Roman's model works.
• I need help coordinating labs → Choose a platform that includes lab ordering (some compounded-only platforms offer this, Roman does not).

Step 6: Are you price-sensitive, or is brand recognition more important?

• Price-sensitive → Compounded-only platforms save $50 to $150/month at maintenance dose.
• Brand recognition matters → Roman has higher brand awareness and a more polished user experience.

If you reach step 6 and brand recognition is your priority, Roman is a defensible choice. If you reach step 6 and price is your priority, compounded-only platforms deliver equivalent clinical outcomes at lower cost.

What we see in patients who switch from Roman to compounded alternatives

A consistent pattern emerges in our intake data from patients who previously used Roman and switched to FormBlends or similar compounded-only platforms.

Reason 1: Cost accumulation. The most common driver. Patients start Roman at $149/month, tolerate the medication well, escalate to maintenance dose, and face $349/month ongoing cost. Over 12 months, the cumulative difference between Roman and a compounded-only platform is $600 to $1,200. For patients paying out-of-pocket, this is meaningful.

Reason 2: Formulation switching fatigue. Patients report frustration with inconsistent product delivery. One month they receive pens, the next month syringes. One batch causes injection site redness, the next does not. The medication works, but the experience feels unstable.

Reason 3: Desire for tirzepatide access. Some patients respond better to tirzepatide (dual GLP-1/GIP agonist) than to semaglutide (GLP-1 only). Roman does not offer tirzepatide. Patients who want to trial both medications switch to platforms that compound both.

Reason 4: Lab coordination gaps. Patients expect their telehealth platform to coordinate baseline and follow-up labs. Roman's model assumes patients will handle this independently. Some patients find this burdensome and switch to platforms that include lab ordering.

The pattern we do NOT see: patients switching because of efficacy differences. Compounded semaglutide works as well as FDA-approved semaglutide for the vast majority of patients. The switches are driven by cost, convenience, and formulation consistency, not by clinical outcomes.

[Diagram suggestion: A Sankey flow diagram showing patient movement from Roman to compounded-only platforms, with flow width proportional to the four reasons above. Cost accumulation would be the widest flow, followed by formulation switching, tirzepatide access, and lab coordination.]

The contrary view: when Roman is the better choice

The strongest argument for Roman over compounded-only platforms is regulatory preference.

Some patients (and some clinicians) place significant value on FDA approval as a quality signal. The FDA's review process includes manufacturing inspections, batch testing, stability studies, and post-market surveillance that compounded medications do not undergo. For patients who view this oversight as essential, paying a premium for access to FDA-approved Wegovy (when available) is rational.

The counterargument is that FDA approval applies to the finished drug product, not to the active ingredient. Compounded semaglutide uses the same API (active pharmaceutical ingredient) that Novo Nordisk uses to manufacture Wegovy. The difference is in formulation, not in the molecule itself. For patients who understand this distinction, the premium for FDA approval is harder to justify.

A second argument for Roman: brand trust and user experience. Roman has been operating since 2017, has treated over 2 million patients across multiple therapeutic areas, and has a polished digital platform. The onboarding experience is smooth. The app is well-designed. Customer support is responsive.

Compounded-only platforms vary widely in user experience. Some are professionally run with clinical teams and strong support. Others are thinly staffed operations with minimal oversight. Roman's brand recognition provides a floor of quality assurance that newer platforms may not.

A third argument: optionality during supply stabilization. If FDA-approved GLP-1 supply fully stabilizes in 2026 or 2027 and compounding pharmacies are no longer permitted to prepare semaglutide (because the legal basis is shortage status), Roman's hybrid model allows you to transition seamlessly to FDA-approved medication. Compounded-only platforms would need to pivot their entire business model or shut down.

This scenario is plausible. The FDA has signaled intent to restrict compounding of GLP-1 medications once commercial supply is adequate. If that happens, patients on compounded-only platforms will need to switch to brand-name products or discontinue treatment. Patients on Roman's platform would already have access to FDA-approved options.

The timeline is uncertain. As of April 2026, semaglutide remains on the FDA drug shortage list for most dose strengths. Tirzepatide is also listed. The shortage has persisted for over four years. Whether it resolves in 2026, 2027, or later is unknown.

For patients with a multi-year treatment horizon who want to avoid future disruption, Roman's hybrid model is a form of insurance. You pay more now for continuity later.

FAQ

What is Roman's weight loss program? Roman is a telehealth platform offering semaglutide for weight management through online consultations and home delivery. The service provides either FDA-approved Wegovy or compounded semaglutide depending on supply availability, with pricing starting at $149/month and scaling to $349/month at maintenance dose.

Does Roman use real Wegovy or compounded semaglutide? Both, depending on FDA shortage status and dose availability. When Wegovy is in stock, Roman dispenses the FDA-approved product. During shortages, Roman switches to compounded semaglutide from partner 503A pharmacies. You do not choose which formulation you receive.

How much does Roman weight loss cost per month? Pricing ranges from $149/month at the lowest dose (0.25 mg weekly) to $349/month for compounded semaglutide at maintenance dose (2.4 mg weekly). If you receive FDA-approved Wegovy, the cost is $399 to $449/month at higher doses. Insurance is not accepted.

Is Roman's semaglutide the same as Wegovy? When Roman dispenses FDA-approved Wegovy, yes, it is identical. When Roman dispenses compounded semaglutide, the active ingredient is the same, but the formulation is not FDA-approved and may vary between compounding pharmacy sources.

Does Roman's weight loss program work? Semaglutide is clinically proven to produce an average of 15% total body weight loss over 68 weeks in clinical trials. Roman does not publish platform-specific outcome data, but the medication itself is effective when used consistently. Real-world outcomes are typically 10% to 12% weight loss with good adherence.

Can I use insurance with Roman for weight loss? No. Roman's weight loss program is direct-pay only and does not accept insurance. If you have insurance coverage for Wegovy, you will pay less by using your insurance directly through a traditional pharmacy rather than through Roman.

What is the difference between Roman and compounded semaglutide platforms? Roman offers both FDA-approved and compounded semaglutide depending on supply, with higher pricing and formulation variability. Compounded-only platforms offer consistent compounded formulations at lower cost but never provide access to FDA-approved products.

Does Roman offer tirzepatide (Mounjaro/Zepbound)? No. As of April 2026, Roman's weight loss program offers semaglutide only. Patients interested in tirzepatide need to use a different platform that compounds or prescribes tirzepatide-based medications.

How do I know if I will get FDA-approved or compounded medication from Roman? You do not know in advance. Roman assigns the formulation based on current supply availability for your prescribed dose. The formulation can change between refills as supply conditions change.

What happens if I have side effects on Roman's semaglutide? You report side effects through the Roman app or website. A provider reviews your report and may adjust your dose, recommend symptom management strategies, or discontinue treatment if side effects are severe. Standard GLP-1 side effects (nausea, diarrhea, constipation) are common and usually resolve within 2 to 4 weeks.

Can I switch from Roman to a compounded-only platform mid-treatment? Yes. If you have an active prescription for semaglutide, you can transfer care to another telehealth platform. You will need a new consultation with the new platform's provider, but your dose history and tolerance can inform the new prescription. Most patients switch without interruption.

Does Roman provide lab testing for weight loss patients? No. Roman recommends baseline and follow-up labs (metabolic panel, lipid panel, A1c, thyroid function) but does not coordinate or pay for lab work. Patients must arrange labs independently through their primary care provider or a lab service like Quest or LabCorp.

Is Roman's weight loss program worth the cost compared to alternatives? It depends on your priorities. If you value potential access to FDA-approved Wegovy and prefer a well-known brand, Roman is worth considering despite higher cost. If you prioritize cost savings and formulation consistency, compounded-only platforms offer equivalent clinical outcomes at $50 to $150/month less.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
6. Patel D et al. Quality assessment of compounded semaglutide products from 503A pharmacies. Journal of Pharmaceutical Sciences. 2023.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Diabetes, Obesity and Metabolism. 2023.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Smits MM et al. Safety of Semaglutide. Frontiers in Endocrinology. 2021.
10. Andersen A et al. Glucagon-like peptide 1 in health and disease. Nature Reviews Endocrinology. 2018.
11. Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. 2018.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
13. Knudsen LB et al. The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology. 2019.
14. FDA Drug Shortages Database. Semaglutide injection shortage status. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Roman, Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Roman, Novo Nordisk, Eli Lilly, or any other mentioned company.